Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 4/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15664318 | 0.87 | SMN1; SMN2 (0.44) | ALDH1A1GAATP53KDM4EMAPK1 | |
| SCHEMBL15664465 | 0.85 | LMNA (0.47) | ALDH1A1GAAKDM4ECYP3A4LMNA | |
| SCHEMBL15664333 | 0.84 | LMNA (0.43) | ALDH1A1GAAPOLBTP53KDM4E | |
| SCHEMBL15663559 | 0.84 | ALDH1A1 (0.46) | ALDH1A1GAAPOLBKDM4EHSD17B10 | |
| SCHEMBL15663563 | 0.80 | NPC1 (0.46) | ALDH1A1POLBTP53CYP3A4CYP2D6 | |
| SCHEMBL15663920 | 0.78 | SMN1; SMN2 (0.40) | ALDH1A1GAAPOLBTP53KDM4E | |
| SCHEMBL20974085 | 0.77 | MALT1 (0.50) | MAPK1HTTKMT2A | |
| SCHEMBL15571180 | 0.77 | ALDH1A1 (0.57) | ALDH1A1POLBKDM4EMAPK1CA12 | |
| SCHEMBL16197755 | 0.77 | ALDH1A1 (0.57) | ALDH1A1POLBKDM4EMAPK1CA12 | |
| SCHEMBL12942067 | 0.77 | ALDH1A1 (0.56) | ALDH1A1GAAPOLBTP53KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3313832-B1 | 3-TETRAZOLYL-BENZENE-1,2-DISULFONAMIDE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME (US) | 2021-02-24 | — | — | EP | disclosed |
| US-10221163-B2 | Metallo-beta-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20180244656-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-08-30 | — | — | US | disclosed |
| EP-1663245-B1 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2010-04-07 | — | — | EP | disclosed |
| US-7192943-B2 | Cephem compounds | ASTELLAS PHARMA INC. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-20050096306-A1 | Cephem compounds | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096306-A1 | Cephem compounds | CEP170, ASS1, C1S | ALDH1A1 1854/4885GAA 3639/4885POLB 3873/4885 |
| US-10221163-B2 | Metallo-beta-lactamase inhibitors | MLX, ZFX, MMP12 | ALDH1A1 259/4885GAA 4/4885POLB 1762/4885 |
| US-20180244656-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MLX, ZFX, MMP12 | ALDH1A1 259/4885GAA 4/4885POLB 1762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.